๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Erythropoietin production rate in phlebotomy-induced acute anemia

โœ Scribed by N.H. Al-Huniti; J.A. Widness; R.L. Schmidt; P. Veng-Pedersen


Book ID
101702056
Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
134 KB
Volume
25
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Objective. To estimate the rate of erythropoietin (EPO) production under physiological, conditions and to examine the regulatory mechanism of EPO production in response to acute phlebotomyโ€induced anemia.

Methods. Six sheep each underwent two phlebotomies in which the hemoglobin (Hb) was reduced to 3โ€“4 g/dl over 4โ€“5 h. The EPO plasma level, reticulocytes, Hb and EPO clearance were followed by frequent blood sampling. The EPO production rate was determined by a semiโ€parametric method based on a disposition decomposition analysis that accounts for the nonlinear disposition kinetics of EPO and corrects for timeโ€dependent changes in the clearance.

Results. The controlled drop in hemoglobin resulted in an abrupt increase in the plasma EPO concentration (peak level 812 ยฑ 40 mU/ml, mean ยฑ CV%) that was followed by a rapid drop 2โ€“4 days after the phlebotomy at a time when the sheep were still anemic (Hb = 4.3 ยฑ 16 g/dl). The EPO production rate at baseline was 43 ยฑ 52 U/day/kg and the amounts of EPO produced over an 8 day period resulting from the first and second phlebotomy were 2927 ยฑ 40 U/kg and 3012 ยฑ 31 U/kg, respectively.

Conclusions. The rapid reduction in the EPO plasma level observed 2โ€“4 days following the phlebotomy cannot be explained solely by the increase in EPO clearance but also by a reduction in EPO production. Copyright ยฉ 2004 John Wiley & Sons, Ltd.


๐Ÿ“œ SIMILAR VOLUMES


Recombinant erythropoietin in acute chem
โœ Beck, Maja Nenadov ;Beck, Daniel ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 444 KB

## Abstract Chemotherapyโ€induced anemia in children with cancer is usually of acute onset. To investigate an alternate treatment to transfusion (Tx), we undertook a phase Iโ€II clinical trial of daily administrations of recombinant erythropoietin (rHuEPO). Patients with a hemoglobin (Hgb) value <75